RECEPTORAI Highlights Advisor’s Kinase Research, Underscoring Drug Discovery Credentials

According to a recent LinkedIn post from RECEPTORAI, the company is highlighting scientific work by its Chief Scientific Advisor, Dr. Rajiah Aldrin Denny, who recently coauthored a Nature Communications study on PF-07245303. The molecule is described as a dual ITK/TRKA inhibitor discovered during his tenure at Pfizer and explored as a potential candidate for atopic dermatitis.

The post notes that TRKA activity was not an original design objective but emerged during compound optimization and was retained as a potentially beneficial polypharmacology feature for atopic dermatitis. The study is said to show strong biochemical activity, with reported IC50 values of 5.62 nM for ITK and 7.2 nM for TRKA, along with target engagement in human skin explants.

According to the summary, PF-07245303 demonstrated inhibition of NGF-induced TRKA phosphorylation and a reduction in resident T cell–associated cytokine responses in ex vivo models. While the compound and study originate from Pfizer, RECEPTORAI’s emphasis on this work suggests it is associating its advisory bench with advanced kinase-focused drug discovery and complex polypharmacology strategies.

For investors, this emphasis may indicate that RECEPTORAI is positioning itself as a platform or discovery player with strong scientific credentials in immunology and dermatology-related pathways rather than announcing a proprietary asset. Demonstrated expertise in interpreting and leveraging kinase inhibitor profiles could enhance the company’s credibility with pharma partners and support potential business development opportunities in drug discovery collaborations.

The post also underscores the importance of integrating mechanistic insights, such as dual ITK/TRKA modulation, into early-stage discovery and optimization. If RECEPTORAI’s internal technology or services are aligned with this type of high-precision target work, the association with peer-reviewed research in a high-impact journal could incrementally strengthen its competitive positioning in the AI- and data-driven drug discovery space.